Form 4: FibroGen Director Benjamin Cravatt Acquires 70,000 Stock Options

Director Benjamin Cravatt acquired 70,000 stock options in FibroGen, Inc. on June 5, 2024, at an exercise price of $1.21.

Summary

• On June 5, 2024, Benjamin Cravatt, a director of FibroGen, Inc., acquired 70,000 stock options.
• The exercise price of these options is $1.21.
• The options vest on the earlier of June 16, 2025, or the date of the next annual meeting of stockholders, contingent upon continuous service.
• The expiration date for these options is June 4, 2034.
• Following the transaction, Cravatt directly owns 70,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard Form 4 filing indicating a director's acquisition of stock options, which can be seen as a positive sign of confidence, but it doesn't provide enough information to strongly skew the sentiment.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders (officers, directors, or those holding more than 10% of the company's shares) buy or sell the company's securities. These filings provide transparency into insider transactions and are closely watched by investors for signals about a company's prospects.

Stakeholder Impact

• Shareholders may view the director's acquisition of stock options as a positive signal, potentially influencing their investment decisions.

Key Dates